Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(15/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(15/week)
News
United States
(1278/week)
Manufacturing
(640/week)
Energy
(502/week)
Technology
(1304/week)
Other Manufacturing
(441/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Myeloproliferative neoplasm
Jul 02, 2018
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Jun 27, 2018
Juntendo University Research: Mutant Chaperone Molecule Triggers Cancer
Jun 15, 2018
JAK Inhibitors Associated with Aggressive Lymphoma
Jun 13, 2018
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
May 03, 2018
NCCN Offers Free Webinar to Address Patient and Caregiver Questions About a Group of Rare Blood Cancers
Mar 09, 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Jan 23, 2018
QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms
Dec 10, 2017
PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
Dec 07, 2017
New Myeloid Research Assay Combines Simultaneous DNA and RNA Analysis of Most Relevant Hematologic Cancer Driver Genes
Oct 19, 2017
New Patient Guidelines from the National Comprehensive Cancer Network Offer Much-Needed Clarity around a Group of Rare Blood Cancers
Sep 19, 2017
Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis
Aug 02, 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
Aug 01, 2017
CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib
Jun 25, 2017
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
‹‹
Page 2
Latest News
May 24, 2024
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers
May 24, 2024
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
May 24, 2024
Comvest Partners Announces $70 Million Senior Credit Facility For Nationwide Energy Partners to Support...
May 24, 2024
On Elects Laura Miele as a New Independent Member of the Board of Directors
May 24, 2024
SatixFy Announces First Quarter 2024 Results
May 24, 2024
Belden Declares Quarterly Dividend
May 24, 2024
Eagle Materials Declares Quarterly Dividend
May 24, 2024
Proposed Channel User Fee Outlined in Special Public Meeting
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events